Across TCGA pan-cancer cohorts, ZBTB9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZBTB9 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher ZBTB9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZBTB9 expression acts as an unfavorable survival marker.

THYM, HNSC, and LIHC are the cancer types where ZBTB9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
HNSC	OS	Median	All	0.220	0.688	.002	21	view →
LIHC	DFS	Median	III,IV	0.040	0.361	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ZBTB9 tumor-vs-normal RNA expression · all ZBTB9 data types